Cue Biopharma (CUE) Osake Kurssi
Cue Biopharma Kurssi
Viimeisten 7 vuoden aikana Cue Biopharman liikevaihto kasvoi 57,5 % vuodessa ja ylsi 27,47 M USD:een. Cue Biopharman nettomarginaali −96,9 % on noussut verrattuna −295,6 %:iin muutama vuosi sitten. Cue Biopharman 12 kuukauden konsensustavoitehinta on 5,10 USD, noin ali kurssia 69,5 %. 6 analyytikosta 5 suosittaa ostoa — kokonaiskonsensus on Osta.
Cue Biopharma osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Cue Biopharma liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Cue Biopharma -osakkeesta
Cue Biopharma Inc is a biotechnology company with a unique business model. It focuses on developing a novel class of biologics called immuno-modulatory proteins (CMPs) to treat a wide range of cancers and autoimmune diseases. By leveraging its Cue Biologics platform, the company aims to engineer CMPs that can selectively modulate immune responses, enhancing the body's ability to fight diseases effectively. Cue Biopharma Inc's business model revolves around creating innovative therapies that leverage the power of the immune system, offering a promising approach in the field of precision medicine.
Cue Biopharma Inc is primarily active in the biotechnology industry.
The main competitors of Cue Biopharma Inc in the market include leading biopharmaceutical companies such as Bristol-Myers Squibb, Eli Lilly and Company, and Merck & Co. These companies also operate in the field of immunotherapy and targeted biologics, which aligns with Cue Biopharma's focus on developing novel biologic therapies for various diseases. Through their extensive research and development efforts, these competitors strive to provide innovative treatments that can effectively address the unmet medical needs of patients.
Cue Biopharma Inc is a biopharmaceutical company founded in 2015. The company focuses on developing innovative immunotherapy drugs for the treatment of various cancers and autoimmune diseases. Cue Biopharma combines insights from immunology and protein engineering to create drugs that enhance the body's immune response against these diseases. With a strong emphasis on precision medicine, Cue Biopharma aims to address the limitations of current treatment options by developing therapies that target specific disease-causing molecules. Through its cutting-edge platform, the company is committed to advancing the field of immunotherapy and improving patient outcomes.
Cue Biopharma Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in October 2017, raising $66.5 million. Cue Biopharma Inc has advanced multiple programs and entered into several strategic partnerships. It has collaborated with Merck under a multi-year collaboration to develop a potential treatment for cancer. Furthermore, Cue Biopharma Inc has leveraged its proprietary platform technology, Immuno-STAT, to create a pipeline of potential immunotherapies targeting various diseases. The company has made remarkable progress in the field of biopharmaceuticals, positioning itself as a leader in the development of innovative immunotherapeutics.
Cue Biopharma Inc is primarily present in the United States.
Cue Biopharma Inc represents values of innovation, dedication, and collaboration in the biopharmaceutical industry. The company strives to develop novel and advanced immunotherapies to address critical unmet needs for patients. With a corporate philosophy centered around precision medicine and immuno-oncology, Cue Biopharma is committed to harnessing the power of the immune system to fight against cancer and other diseases. By leveraging its innovative Immuno-STAT™ platform, the company aims to create highly targeted therapies that can revolutionize the treatment landscape. Cue Biopharma's focus on cutting-edge science and strategic partnerships reflects its dedication to improving patient outcomes and advancing the field of immunotherapy.
Analyytikot asettavat tällä hetkellä Cue Biopharma-osakkeelle keskimääräisen tavoitehinnan 5,10 USD (mediaani: 5,10 USD), mikä merkitsee −69,5 % viimeisimpään hintaan verrattuna. Konsensus perustuu 6 analyytikkoarvioon.
6 analyytikkoa arvioi tällä hetkellä Cue Biopharma-osaketta: 5 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Cue Biopharma-yhtiöltä 15,62 M USD liikevaihtoa ja −534,58 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Cue Biopharma-osake noteerataan hintaan 14,87 EUR (16,71 USD).
Cue Biopharma-osake (CUE) on listattuna 3 pörssissä, muun muassa: NASDAQ (CUE), Frankfurt (1UC.F), München (1UC.MU).
Cue Biopharma Inc is a biopharmaceutical company specializing in the development of immunotherapies for the treatment of cancer and autoimmune diseases. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts. The business model of Cue Biopharma Inc is based on the use of immunotherapies targeting the body's immune system to fight cancer and autoimmune diseases. The company utilizes a unique platform called Immuno-STATs (Signal Transducer and Activator of Transcription Proteins) to create artificial proteins specifically targeting T cells in the immune system. These proteins can then be used to selectively activate the immune system and attack diseased cells in the body. Cue Biopharma Inc focuses on developing tailored immunotherapies customized to each patient's individual needs. The company is divided into several business areas, including research and development, clinical trials, and commercial production. Cue Biopharma Inc collaborates closely with leading researchers and scientists in the field of immunology to leverage the latest advancements and technologies. Cue Biopharma Inc currently offers several products, including CUE-101, CUE-102, and CUE-103. CUE-101 is an immunotherapeutic currently in phase 1 clinical trial for the treatment of HPV-associated cancer. CUE-102 and CUE-103 are still in preclinical development but have shown promising results in studies. CUE-103 is primarily intended for the treatment of autoimmune diseases such as type 1 diabetes and rheumatoid arthritis. The company is committed to continuously researching and developing better and more targeted immunotherapies to help millions of people worldwide. In summary, Cue Biopharma Inc is an innovative company specializing in the development of tailored immunotherapies for the treatment of cancer and autoimmune diseases. The company utilizes a unique technology to selectively activate the immune system and attack diseased cells in the body. Through close collaboration with leading researchers and scientists in the field of immunology, as well as ongoing research and development, the company aims to develop increasingly better and more effective therapies.
odotettu liikevaihto Cue Biopharma on 15,62 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Cue Biopharma on −1,97 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Cue Biopharma:n hinta-voitto-suhde (P/E) on tällä hetkellä −0,03. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Cue Biopharma-osakkeen arvostusta.
Cue Biopharma:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,94. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Cue Biopharma-osakkeen arvostuskennuslukuna.
Cue Biopharma:n Eulpool-laatuscore on 4/10.
Cue Biopharma:n ISIN on US22978P1066. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Cue Biopharma:n WKN on A2JAT5. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Cue Biopharma:n ticker on CUE. Tämä pörssinoteeraus käytetään Cue Biopharma-osakkeiden kauppaan pörssissä.
Cue Biopharma osake
Cue Biopharma vertaisryhmä
Cue Biopharma Ticker
Cue Biopharma FIGI
Kaikki tunnusluvut ja syvällinen analyysi Cue Biopharma:sta
Meidän osakeanalyysimme Cue Biopharma-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Cue Biopharma:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: